439 | ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB + LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Documenti analoghi

• 815 | GLOFITAMAB MONOTHERAPY IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL ANALYSIS OF A PHASE I TRIAL
  di: Y. Song, et al.
  Pubblicazione: (2025)
• 666 | OUTCOMES OF RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN AN ASIAN MULTIETHNIC COHORT
  di: N. Lim, et al.
  Pubblicazione: (2025)
• 816 | FIRST DATA DISCLOSURE FROM PHASE 1B/2 EPCORE NHL‐4: EPCORITAMAB IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
  di: W. Zhao, et al.
  Pubblicazione: (2025)
• 148 | GOLCADOMIDE ± RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: UPDATED PHASE 1/2 RESULTS
  di: E. Bachy, et al.
  Pubblicazione: (2025)
• 636 | GLOFITAMAB COMBINED WITH SALVAGE THERAPY FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A REAL‐WORLD PROSPECTIVE OBSERVATIONAL STUDY IN CHINESE PATIENTS
  di: H. Huang
  Pubblicazione: (2025)